DTRA Awards Mount Sinai $20.7M for Inhaled mRNA Vaccine Research
The Defense Threat Reduction Agency awarded Icahn School of Medicine at Mount Sinai an approximately $20.7 million, five-year agreement through its RAVEN program. The effort will develop and evaluate an inhaled/nasal mRNA vaccine platform, initially targeting H5N1 and assessing adaptability to at least 20 respiratory viruses; it is an award, not an open solicitation.